Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors


Study Number
54317
Phase
2
Purpose

The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Full Title

First-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax-AXL-ADC) in patients with solid tumors

ClinicalTrials.Gov ID
NCT02988817

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.